Upadacitinib
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Upadacitinib is used to treat rheumatoid arthritis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Aug 16, 2019. In 2024, Medicare Part D spent $1.4 billion on Upadacitinib across 194,000 claims for 29,000 beneficiaries.
Upadacitinib is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $229.29 to $459.62 per EA — the most expensive product costs about 2.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$229.29 – $459.62
per EA
7d Activity
avg +0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
AbbVie Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Janus Kinase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing UPADACITINIB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
RINVOQ ER 45 MG TABLET | $459.6225 per EA | +0.05% |
RINVOQ ER 15 MG TABLET | $229.3090 per EA | +0.01% |
RINVOQ ER 30 MG TABLET | $229.2939 per EA | +0.02% |
Frequently Asked Questions
What is Upadacitinib used to treat?
Upadacitinib is used to treat rheumatoid arthritis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Upadacitinib?
In 2024, Medicare Part D spent $1.4 billion on Upadacitinib across 194,000 claims for 29,000 beneficiaries.
How many Upadacitinib products are on the market?
The Upadacitinib drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Upadacitinib?
NADAC reference prices for Upadacitinib range from $229.2939 to $459.6225 per EA — the most expensive product costs about 2.0× the cheapest.
Which manufacturers make Upadacitinib?
1 manufacturer lists Upadacitinib in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (3).
How has the price of Upadacitinib changed recently?
Over the past 7 days, 3 Upadacitinib NDCs rose and 0 fell, with a market-wide average change of +0.0%.